Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03158883 · ClinicalTrials.gov registry record · Early Phase 1
UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients
A Early Phase 1 study, sponsored by Megan Daly, MD.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT03158883: Completed Early Phase 1 study, sponsored by Megan Daly, MD.
NCT03158883 is a Early Phase 1 study that has completed, run by Megan Daly, MD. The registered enrollment target is 8 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03158883, a Early Phase 1 study, has completed, sponsored by Megan Daly, MD.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a pilot, single center, open-label study to examine the ORR, safety, and toxicity of avelumab in combination with SAR in non-responding and progressing NSCLC patients previously treated with a PD-1 Inhibitor.
Primary Outcome
Response and progression will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria.
Interventions
- DRUG Avelumab
- RADIATION Stereotactic ablative radiotherapy (SAR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-05-17 |
| Est. Completion | 2020-06-24 |
| Phase | Early Phase 1 |
What the finished NCT03158883 record still lists
NCT03158883 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Avelumab is the first listed.
NCT03158883 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03158883 about?
NCT03158883 is a clinical study titled "UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients". This is a pilot, single center, open-label study to examine the ORR, safety, and toxicity of avelumab in combination with SAR in non-responding and progressing NSCLC patients previously treated with a PD-1 Inhibitor.
What is the current status of trial NCT03158883?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2017-05-17. Estimated completion is 2020-06-24.
What interventions are being tested in trial NCT03158883?
The interventions under investigation include: Avelumab (DRUG), Stereotactic ablative radiotherapy (SAR) (RADIATION).
Who is sponsoring clinical trial NCT03158883?
This trial is sponsored by Megan Daly, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03158883's enrollment target sits among peer trials
8 1783rd of 2000 higher than 176 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI